Login
$TEM
$67.06 +$2.30 (3.55%) After hours

$TEM SEC Filings

Filed On Filing
06 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 Form 4: Epstein David R, Director

Sold 370 shares ($27.5K)

04 Nov 2026 Form 4: Fukushima Ryan, CEO, Data

Received 100,000 shares as a grant or award · Sold 80 shares ($5.94K)

02 Nov 2026 144
02 Nov 2026 10-Q
02 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

CHICAGO, November 2, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.

29 Oct 2026 Form 4: Lefkofsky Eric P, Director

Sold 250,000 shares ($17.6M)

28 Oct 2026 SCHEDULE 13G/A
27 Oct 2026 144
23 Oct 2026 8-K: Other Events

On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal rea...

21 Oct 2026 EFFECT
21 Oct 2026 424B3
20 Oct 2026 S-4/A
02 Oct 2026 S-4/A
29 Sep 2026 Form 4: Schoenherr Thomas Edward, CEO, Diagnostics

Sold 10,281 shares ($874K)

25 Sep 2026 144
24 Sep 2026 Form 4: Lefkofsky Eric P, Director

Sold 250,000 shares ($19.4M)

22 Sep 2026 144
18 Sep 2026 Form 4: Lefkofsky Eric P, Director

Sold 200,000 shares ($16.1M)

18 Sep 2026 Form 4: Bartolucci Ryan M, Chief Accounting Officer

Sold 7,062 shares ($530K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support